Multivalent liposome-based vaccines containing different serosubtypes of PorA protein induce cross-protective bactericidal immune responses against Neisseria meningitidis - PubMed (original) (raw)
Multivalent liposome-based vaccines containing different serosubtypes of PorA protein induce cross-protective bactericidal immune responses against Neisseria meningitidis
Holly E Humphries et al. Vaccine. 2006.
Abstract
Four serosubtypes (P1.7, 16, P1.7-2, 4, P1.19, 15 and P1.5-1, 10-4) of the PorA outer-membrane protein of Neisseria meningitidis were purified as recombinant proteins and incorporated into liposomes to investigate their immunogenicity. Each serosubtype induced high levels of bactericidal activity against the homologous strain. In addition, liposome preparations containing multiple serosubtypes induced high levels of bactericidal activity against each of the four strains. Significantly, antisera raised against monovalent and multivalent liposomes also showed cross-reactive bactericidal activity against heterologous strains. These data demonstrate that multivalent liposome vaccines, containing multiple PorA serosubtypes, have the potential to provide protection against a broad range of meningococcal strains.
Similar articles
- Recombinant meningococcal PorA protein, expressed using a vector system with potential for human vaccination, induces a bactericidal immune response.
Humphries HE, Williams JN, Christodoulides M, Heckels JE. Humphries HE, et al. Vaccine. 2004 Mar 29;22(11-12):1564-9. doi: 10.1016/j.vaccine.2003.09.042. Vaccine. 2004. PMID: 15063582 - Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccine.
Luijkx T, van Dijken H, van Els C, van den Dobbelsteen G. Luijkx T, et al. Vaccine. 2006 Mar 6;24(10):1569-77. doi: 10.1016/j.vaccine.2005.10.003. Epub 2005 Oct 24. Vaccine. 2006. PMID: 16298029 - Serosubtypes and PorA types of Neisseria meningitidis serogroup B isolated in Brazil during 1997--1998: overview and implications for vaccine development.
Sacchi CT, Lemos AP, Popovic T, De Morais JC, Whitney AM, Melles CE, Brondi LM, Monteiro LM, Paiva MV, Solari CA, Mayer LW. Sacchi CT, et al. J Clin Microbiol. 2001 Aug;39(8):2897-903. doi: 10.1128/JCM.39.8.2897-2903.2001. J Clin Microbiol. 2001. PMID: 11474010 Free PMC article. - Immunization with recombinant Opc outer membrane protein from Neisseria meningitidis: influence of sequence variation and levels of expression on the bactericidal immune response against meningococci.
Jolley KA, Appleby L, Wright JC, Christodoulides M, Heckels JE. Jolley KA, et al. Infect Immun. 2001 Jun;69(6):3809-16. doi: 10.1128/IAI.69.6.3809-3816.2001. Infect Immun. 2001. PMID: 11349046 Free PMC article. - Innate immune function of the neisserial porins and the relationship to vaccine adjuvant activity.
Wetzler LM. Wetzler LM. Future Microbiol. 2010 May;5(5):749-58. doi: 10.2217/fmb.10.41. Future Microbiol. 2010. PMID: 20441547 Free PMC article. Review.
Cited by
- Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge.
LoBue AD, Thompson JM, Lindesmith L, Johnston RE, Baric RS. LoBue AD, et al. J Virol. 2009 Apr;83(7):3212-27. doi: 10.1128/JVI.01650-08. Epub 2009 Jan 28. J Virol. 2009. PMID: 19176631 Free PMC article. - The influence of genomics and proteomics on the development of potential vaccines against meningococcal infection.
Heckels JE, Williams JN. Heckels JE, et al. Genome Med. 2010 Jul 22;2(7):43. doi: 10.1186/gm164. Genome Med. 2010. PMID: 20670394 Free PMC article. - Multivalent Interactions: Synthesis and Evaluation of Melanotropin Multimers - Tools for Melanoma Targeting.
Brabez N, Saunders K, Nguyen KL, Jayasundera TB, Weber C, Lynch RM, Chassaing G, Lavielle S, Hruby VJ. Brabez N, et al. ACS Med Chem Lett. 2013 Jan 1;4(1):98-102. doi: 10.1021/ml300312b. Epub 2012 Nov 24. ACS Med Chem Lett. 2013. PMID: 23524643 Free PMC article. - Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.
Watson DS, Endsley AN, Huang L. Watson DS, et al. Vaccine. 2012 Mar 16;30(13):2256-72. doi: 10.1016/j.vaccine.2012.01.070. Epub 2012 Feb 2. Vaccine. 2012. PMID: 22306376 Free PMC article. Review. - Coincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: influence on endotoxic and adjuvant activity.
Arenas J, van Dijken H, Kuipers B, Hamstra HJ, Tommassen J, van der Ley P. Arenas J, et al. Clin Vaccine Immunol. 2010 Apr;17(4):487-95. doi: 10.1128/CVI.00423-09. Epub 2010 Jan 27. Clin Vaccine Immunol. 2010. PMID: 20107001 Free PMC article.